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Abstract
MicroRNA-34a (miR-34a), a potent mediator of tumor suppressor p53, has been reported to function as a tumor suppressor
and miR-34a was found to be downregulated in prostate cancer tissues. We studied the functional effects of miR-34a on c-
Myc transcriptional complexes in PC-3 prostate cancer cells. Transfection of miR-34a into PC-3 cells strongly inhibited in vitro
cell proliferation, cell invasion and promoted apoptosis. Transfection of miR-34a into PC-3 cells also significantly inhibited in
vivo xenograft tumor growth in nude mice. miR-34a downregulated expression of c-Myc oncogene by targeting its 39 UTR
as shown by luciferase reporter assays. miR-34a was found to repress RhoA, a regulator of cell migration and invasion, by
suppressing c-Myc–Skp2–Miz1 transcriptional complex that activates RhoA. Overexpression of c-Myc reversed miR-34a
suppression of RhoA expression, suggesting that miR-34a inhibits invasion by suppressing RhoA through c-Myc. miR-34a
was also found to repress c-Myc-pTEFB transcription elongation complex, indicating one of the mechanisms by which miR-
34a has profound effects on cellular function. This is the first report to document that miR-34a suppresses assembly and
function of the c-Myc–Skp2–Miz1 complex that activates RhoA and the c-Myc-pTEFB complex that elongates transcription
of various genes, suggesting a novel role of miR-34a in the regulation of transcription by c-Myc complex.
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Introduction
MicroRNAs (miRNAs) are highly conserved, single stranded,
non-coding RNAs of approximately 22 nucleotides that regulate
gene expression by posttranscriptional silencing of specific target
mRNAs, by repressing translation or cleaving RNA transcripts [1].
miRNAs regulate diverse cellular processes such as cell-cycle
progression, proliferation, apoptosis and development. miRNAs
have been shown to function as oncogenes or tumor suppressor
genes [2].
The p53 tumor suppressor is deleted or mutated in more than
50% of human tumors and is a key molecule which suppresses
malignancies [3]. p53 has been found to target the miR-34 family
[4,5,6] and the ectopic expression of miR-34 genes has drastic
effects on cell proliferation and survival. Ectopic miR-34a causes
cell-cycle arrest in the G1 phase [6,7] and apoptosis [7,8]. As p53
has been found to target miR-34a and since, cell-cycle arrest and
apoptosis are also end points of p53 activation, the miR-34a gene
may be a mediator of p53 function.
The proto-oncogene c-Myc regulates cell proliferation and
transformation both transcriptionally and non-transcriptionally
and is frequently deregulated in human cancers [9,10]. c-Myc is a
basic helix–loop–helix and leucine zipper transcription factor
which binds to Enhancer Box elements (E-boxes) and activates the
transcription of genes which stimulate cell cycle progression and
cell growth. c-Myc suppresses the transcription of genes which
arrest the cell cycle, through Miz1, the c-Myc associated protein.
c-Myc also has a function to recruite histone acetyltransferases
(HATs). c-Myc non-transcriptionally interacts with components of
the replication machinery to positively regulate DNA synthesis,
leading to genomic instabilities.
c-Myc was reported to activate MiR-17-92, a polycistronic
microRNA cluster consisting of miR-17, 18a, 19a, 20a, 19b and
92a [11,12]. miR-19 was found to be the principal oncogenic
component of this cluster, targeting the tumour suppressor PTEN
[13]. miR-34c has been shown to negatively regulate c-Myc in
response to DNA damage and to inhibit c-Myc-induced DNA
synthesis [14]. During oncogene-induced senescence, miR-34a
was also found to target c-Myc [15].
Rho GTPases are small G proteins that regulate various cellular
processes, including cytoskeletal dynamics, migration, vesicle
trafficking, cell proliferation, apoptosis, and transcription
[16,17,18]. Rho GTPases, their regulators, and their effectors
have been suggested to control tumor formation and progression.
RhoA has been shown to control cancer metastasis and
progression [19,20,21]. Recently, c-Myc complex was found to
activate the RhoA gene [22].
The positive transcription elongation factor b (P-TEFb)
regulates the promoter-proximal pause release of the elongation
phase of transcription by Pol II [23] and integrates mRNA
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synthesis with histone modification, pre-mRNA processing and
mRNA export [24]. P-TEFb is composed of cyclin (CycT1,
CycT2a, CycT2b or CycK) and cyclin-dependent kinase 9 (Cdk9)
[23]. c-Myc interacts with cyclin T1 (CycT1), the regulatory
component of P-TEFb, and controls the elongation phase of
transcription by Pol II [25,26,27].
The c-Met pathway is dysregulated in most human malignan-
cies and regulates tumor formation and progression [28,29]. c-Met
interacts with hepatocyte growth factor/scatter factor and has
been implicated in tumor invasion and migration including PC-3
cells [30,31,32,33,34,35].
We report here that miR-34a was downregulated in prostate
cancer tissues. miR-34a inhibited cell proliferation in vitro, in vivo
tumor growth and promoted apoptosis in prostate cancer cells. We
also found miR-34a targets c-Met and inhibits PC-3 cell invasion.
We investigated the effects of miR-34a on the two c-Myc
transcriptional complexes. By targeting c-Myc, miR-34a reduced
the c-Myc-Miz-Skp2 complex which induces RhoA transcription
and inhibited cell invasion, showing that miR-34a indirectly
regulates RhoA. miR-34a also suppressed the c-Myc-P-TEFb
complex that plays a key role in controlling the elongation phase of
transcription by RNA polymerase II (Pol II), indicating one of the
mechanisms by which miR-34a has dramatic effects on cellular
function. Our results demonstrate that in prostate cancer PC-3
cells miR-34a suppresses assembly and function of the c-Myc
complex that activates or elongates transcription, revealing a novel
role of miR-34a in the regulation of transcription by c-Myc.
Results
miR-34a expression is downregulated in prostate cancer
We examined the expression levels of miR-34a in laser capture
microdissected (LCM) prostate cancer tissues (n = 10) and matched
adjacent normal regions by real-time PCR. All cancer tissues
showed lower miR-34a levels compared with matched adjacent
normal regions, demonstrating that miR-34a is downregulated in
cancer (Fig. 1A). Histological data shows that these tissues are
adenocarcinoma with Gleason scores of 6 or 7. Gleason patterns
and other clinical data are shown in Table S1.
We also assayed miR-34a expression levels in malignant (PC-3,
LNCaP and DU145 cells) and non-malignant prostate RWPE-1
cells. Real-time RT-PCR revealed that the expression level of
miR-34a was markedly lower in PC-3 cells compared with non-
malignant epithelial prostate cell RWPE-1 cells (data not shown).
This result was consistent with the previously reported data using
PrEC normal human prostate epithelial cells [36]. We also
compared the expression levels of miR-34a in malignant prostate
cells and the laser capture microdissected (LCM) prostate normal
tissues (n = 10). Real-time RT-PCR showed that the expression
level of miR-34a was lower in malignant prostate cells compared
with the average of the expression level of miR-34a in the normal
tissues (data not shown). These results were also consistent with the
previously reported data using normal human tissues [37].
miR-34a inhibits cell proliferation of PC-3 cells
To study the effect of miR-34a on the growth of prostate cancer
cells, we transiently transfected several cell lines with pre-miR
negative control (NC) or pre-miR-34a. The transient transfection
of pre-miR-34a increased miR-34a levels in prostate cancer cells
(Fig. S1A). MTS assay showed that miR-34a inhibited PC-3 cell
proliferation by about 40% on day 4 but had no significant effect
on LNCaP and DU145 cells (Fig. S2A). A recent report indicates
that PC-3 cells have characteristics of prostatic small cell
carcinoma and not of adenocarcinoma [38], however we used
PC-3 cells for further study because the proliferation suppression
effect of miR-34a was significant, which was consistent with the
previously reported data [36]. Transient transfection of pre-miR-
34a also caused significant morphological changes in PC-3 cells
(Fig. S2B).
We employed a lentiviral system to express miR-34a. The HIV
lentiviral system, expressing miR-34a or vector control, was used
to infect PC-3 cells and the infected cells were selected with
puromycin. The stable transfection of pre-miR-34a increased
miR-34a levels in PC-3 cells (Fig. S1B). We performed soft agar
colony formation assay using the infected PC-3 cells expressing
miR-34a or control. miR-34a reduced colony numbers to about
20% of that of control, showing that miR-34a significantly
inhibited the colony forming ability of PC-3 cells (Figs. 1B and C).
To examine the effects of the ectopic expression of miR-34a on
in vivo tumor growth, we subcutaneously injected the stable miR-
34a or the control cell line into nude mice. Tumor volumes were
measured every 7 days for 5 weeks following the injection.
Xenograft tumors from PC-3 cells overexpressing miR-34a were
smaller than xenograft tumors from the control cells. At week 5,
tumor sizes of control xenografts were about 5 times larger than
those of miR-34a xenografts, indicating that the ectopic expression
of miR-34a significantly suppressed tumor growth in vivo (Figs. 1D
and E).
Since ectopic expression of miR-34a suppressed PC-3 cell
proliferation, we next studied the effects of miR-34a on apoptosis
in PC-3 cells using flow cytometry. We found that ectopic
expression of miR-34a increased PC-3 cell apoptosis to about4
times of that controls (Fig.1F and Fig. S3), demonstrating that
miR-34a has apoptotic activity in PC-3 cells.
miR-34a inhibits cell invasion and migration
We performed a transwell invasion assay using Matrigel to
investigate the effect of miR-34a on the invasive ability of PC-3
cells. We transiently transfected PC-3 cells with pre-miR negative
control (NC) or pre-miR-34a and subjected the transfected cells to
transwell invasion assay. The results clearly revealed that miR-34
reduced invasion of PC-3 cells to 20% of that of controls (Figs. 2A
and B). Wound-healing assay also showed that miR-34a markedly
reduced the migration of PC-3 cells (Figs. 2C and D).
miR-34a targets c-Myc and c-Met
Oncogenes, c-Met and c-Myc, have predicted binding sites for
miR-34a in their 39-UTRs (Fig. S4). c-Met has 2 predicted binding
sites for miR-34a in its 39-UTRs (Fig. S3). We cloned the putative
miR-34a targets in the 39UTRs into a luciferase construct.
Luciferase reporter assays with miR-34a-expressing PC-3 cells
showed that miR-34a repressed luciferase activity. Mutation of the
putative miR-34a target sites in these UTRs decreased the
response to miR-34a. These results indicate that miR-34a binds
to the 39-UTRs of c-Myc and c-Met (Fig. 3A).
We examined the effects of miR-34a transfection on the protein
levels of these genes. Transfection of miR-34a reduced the protein
levels of c-Met and c-Myc, protein in PC-3 cells (Fig. 3B). These
results confirm that miR-34a directly targets c-Met and c-Myc via
binding to their 39UTRs in PC-3 cells. miR-34a also reduced
levels of transcription factor E2F1 which regulates the cell cycle,
DNA replication and cell proliferation (Fig. 3B).
miR-34a inhibits RhoA and suppresses assembly of c-Myc
transcriptional complex
The c-Myc–Skp2–Miz1 transcriptional complex has been found
to activate RhoA gene and to be critical for cell invasion and
miR-34a Targets c-Myc Transcriptional Complexes
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cancer metastasis [22]. Since we found that c-Myc is a target of
miR-34a, thus downregulating the expression of c-Myc, we
examined whether the downregulation of c-Myc by miR-34a
results in reduction of RhoA expression by suppressing assembly of
the c-Myc–Skp2–Miz1 complex. Real-time PCR showed miR-34a
decreased RhoA mRNA level (Fig. 4A) and Western blot revealed
that miR-34a reduced RhoA protein expression (Fig. 4B).
We performed immunoprecipitation (IP) to study assembly of
the c-Myc–Skp2–Miz1 transcriptional complex in miR-34a
transfected cells. IP (Fig. 4C) revealed that anti-c-Myc immuno-
precipitates contained Miz1, Skp2 and Max (lane 5) but not anti-
IgG (control) immunoprecipitates (lane 3), indicating that the c-
Myc–Skp2–Miz1 complex was formed in PC-3 cells. IP also
showed that miR-34a decreased the levels of these components in
the c-Myc immunoprecipitates [lanes 4 (control) and 6], indicating
that miR-34a suppressed assembly of the c-Myc–Skp2–Miz1
transcriptional complex in PC-3 cells. miR-34a did not signifi-
cantly reduce Skp2 in the immunoprecipitates compared with the
other components.
We performed chromatin immunoprecipitation (ChIP) assays to
examine whether miR-34a reduces binding of c-Myc to the RhoA
promoter region containing E-boxes 5 and 6, which is a primary
binding site of c-Myc [22]. The ChIP assay showed that
endogenous c-Myc binds to E-boxes 5 and 6 and control
experiments demonstrated that RNA polymerase II binding to
the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) pro-
Figure 1. miR-34a inhibits cell growth. (A) Relative miR-34a expression in laser capture microdissected (LCM) prostate cancer tissues (C) and
matched adjacent normal regions (N). (B) miR-34a overexpression suppresses soft agar colony formation of a stably transfected miR-34a PC-3 cell line.
After 14 days incubation, colonies with over 50 cells were counted. The values are normalized to those of control. (C) Representative images of the
colonies. (D) miR-34a inhibits in vivo tumor growth. Time course of tumor growth in nude mice after subcutaneous injection of a stably transfected
miR-34a PC-3 cell line or control cell line. *, P,0.05 compared with control. (E) Representative images of tumors in nude mice at 5 weeks after
subcutaneous injection of a stably transfected miR-34a PC-3 cell line or control cell line. (F) miR-34a induces apoptosis in PC-3 cells. PC-3 cells were
transfected with pre-miR negative control (NC) or pre-miR-34a for 3 days. PC-3 cells were stained with AnnexinV-FITC/7-AAD and apoptosis was
analyzed by flow cytometry. The data shows the percentage of early apoptotic and apoptotic cells out of the total cell population of PC-3 cells.
*, P,0.05 compared with control.
doi:10.1371/journal.pone.0029722.g001
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moter was not altered (Fig. 4D). These results suggested that miR-
34a reduced the recruitment of the c-Myc–Skp2–Miz1 complex to
the RhoA promoter and reduces RhoA expression.
Overexpression of c-Myc reverses inhibition of invasion
To determine whether inhibition of invasion by miR-34a could
be reversed via restoration of c-Myc, we transfected PC-3 cells
with a c-Myc expression plasmid together with pre-miR-34a. c-
Myc overexpression partially rescued RhoA expression (Fig. 5A,
compare lane 4 with 3) and miR-34-induced suppression of
invasion (Fig. 5B), suggesting that miR-34a inhibits invasion, at
least partially, via RhoA reduction by targeting c-Myc.
miR-34a suppresses assembly of c-Myc-P-TEFb complex
The positive transcription elongation factor b (P-TEFb) plays a
key role in controlling the elongation phase of transcription by
RNA polymerase II (Pol II) [23]. It is a cyclin-dependent kinase
comprised of Cdk9 andcyclin. c-Myc has been shown to interact
with P-TEFb through CycT1 and regulate transcription elonga-
tion [25,26,27]. Since miR-34a targets c-Myc, we performed
Figure 2. miR-34a inhibits invasion and migration of PC-3 cells. (A) miR-34a inhibits invasion of PC-3 cells. PC-3 cells were transiently
transfected with pre-miR negative control (NC) or pre–miR-34a for 48 h. The cells were harvested and subjected to transwell invasion assay. The
values are normalized to those of NC. *, P,0.05 compared with control. (B) Representative images of the invaded cells. (C) miR-34a inhibits wound-
healing of PC-3 cells. PC-3 cells were transiently transfected with pre-miR negative control (NC) or pre–miR-34a for 48 h. The cells were harvested and
subjected to wound-healing assay. The width of the remaining open wound calculated in relation to separation at time 0 h. *, P,0.05 compared with
control. (D) Representative images of the wound healing assay.
doi:10.1371/journal.pone.0029722.g002
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immunoprecipitation (IP) to study assembly of the c-Myc-pTEFB
transcription elongation complex in mir-34a-transfected PC-3
cells. IP (Fig. 6A) revealed that anti-c-Myc antibody pulled down
CycT1, Cdk9 and Max (lane 5) but IgG (control) did not pull
down these proteins (lane 3), indicating that c-Myc interacted with
P-TEFb. IP also showed that miR-34a decreased the amount of p-
TEFb in the c-Myc immunoprecipitates in PC-3 cells [lanes 4
(control) and 6], indicating that miR-34a suppressed assembly of
the c-Myc–P-TEFb complex in PC-3 cells.
c-Myc was reported to activate transcription of CAD,
carbamoyl-phosphate synthase/aspartate transcarbamoylase/di-
hydroorotase, and NUC by stimulating promoter clearance and
elongation, via recruitment of P-TEFb [25,39,40]. We studied
whether miR-34a affected the expression level of CAD and NUC
using DRB (5.6-di-chloro-1-b-D-ribofuranosyl-bensimidazole)
which specifically suppresses expression of c-Myc-responsive
CAD and NUC by inhibiting P-TEFb [40]. We found that
miR-34a decreased CAD and NUC mRNA expression in PC-3
cells while DRB restored the expression (Fig. 6B). These results
indicate that miR-34a repressed these genes by suppressing the c-
Myc-pTEFb complex.
Overexpression of c-Met reverses inhibition of invasion
It has been suggested that miR-34a inhibits cell invasion in a c-
Met-dependent manner [41,42]. Therefore, we studied effects of
miR-34a on c-Met and invasion since miR-34a targets c-Met
Figure 3. miR-34a targets oncogenes in PC-3 cells. (A) PC-3 cells were transiently transfected with pre-miR negative control (NC) or pre–miR-
34a or pre–miR-con for 8 h, followed by transient transfection with control reporter plasmids or 39UTR plasmids for 48 h. 39UTR reporter activity was
measured by luciferase assay and normalized to activity of Renilla luciferase. *, P,0.05 compared with control. (B) PC-3 cells were transiently
transfected with pre-miR negative control (NC) or pre–miR-34a or pre–miR-con for 72 h. Protein expression level was analyzed by Western blot.
doi:10.1371/journal.pone.0029722.g003
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(Fig. 1). PC-3 cells were transfected with a c-Met expression
plasmid together with pre-miR-34a. c-Met expression levels were
examined by Western blot which indicated that c-Met expression
was increased in the c-Met transfected cells (Fig. 7A). c-Met
promoted invasion in control experiments. c-Met reversed miR-
34-induced suppression of invasion, indicating that miR-34a
inhibits invasion, at least partially, by targeting c-Met (Figs. 7B
and C).
Discussion
In this study we demonstrated for the first time the functional
effects of miR-34a on c-Myc transcriptional complexes in PC-3
prostate cancer cells. We found that miR-34a expression is
downregulated prostate cancer tissue and that miR-34a re-
expression strongly inhibits cell proliferation, in vivo xenograft
growth and cell invasion. We showed that miR-34a inhibited c-Myc
by binding to its 39UTR in PC-3 cells and suppressed assembly of
the c-Myc transcriptional complexes. Mutations of c-Myc are found
in various cancers and its deregulated expression causes the
uncontrolled expression of many genes some of which regulate cell
proliferation and results in tumor development [43,44]. Although c-
Myc alone is not able to transform cells and requires a co-operating
oncogene such as ras oncogene [45], c-Myc is an important factor in
tumor development. Thus, inhibition of c-Myc is thought to be a
significant function of miR-34a. We also showed that miR-34a
inhibited PC-3 cell invasion by targeting c-Met.
Rho GTPases, a family of small G proteins, regulate
intracellular actin dynamics including cell polarity, migration,
vesicle trafficking etc. These molecules also regulate cell
proliferation, apoptosis, gene expression [17]. RhoA, a member
of the Rho family of GTPases, is implicated in transformation and
metastasis. RhoA has been shown to be an important factor
associated with various human cancers [46].
The c-Myc–Skp2–Miz1 transcriptional complex has been
previously shown to activate RhoA and to be essential for cell
Figure 4. miR-34a suppresses the c-Myc transcriptional complex of RhoA. PC-3 cells were transiently transfected with pre-miR negative
control (NC) or pre-miR-34a for 72 h. (A) RhoA mRNA level was analyzed by real-time PCR. (B) RhoA protein expression was analyzed by Western blot.
(C) c-Myc pulls down endogenous Miz1, Skp2 and Max in PC-3 cells. PC-3 cells were transiently transfected with pre-miR negative control (NC) or pre–
miR-34a for 72 h and total cell lysates were immunoprecipitated with c-Myc antibody or IgG (control), followed by Western blot analysis. (D) miR-34a
decreases the recruitment of c-Myc to the RhoA promoter. PC-3 cells were transiently transfected with pre-miR negative control (NC) or pre–miR-34a
for 72 h and ChIP assays were performed. *, P,0.05 compared with control.
doi:10.1371/journal.pone.0029722.g004
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invasion and cancer metastasis [22]. We found that c-Myc is a
target of miR-34a in PC-3 cells, and we studied the effect of miR-
34a on RhoA activation via the c-Myc–Skp2–Miz1 transcriptional
complex. miR-34a reduced RhoA expression and overexpression
of c-Myc reversed the reduction of RhoA and inhibition of cell
invasion. ChIP assay revealed miR-34a suppresses the recruitment
of c-Myc to the RhoA promoter. We demonstrated that miR-34a
suppressed RhoA transcription by reducing the c-Myc–Skp2–
Miz1 transcriptional complex. These data document the fact that
miR-34a suppresses RhoA activation at the initiation of transcrip-
tion via targeting c-Myc. Our results demonstrate that miR-34a
suppresses assembly and function of the c-Myc complex that
activates transcription of RhoA.
The positive transcription elongation factor b (P-TEFb)
regulates the promoter-proximal pause release of the elongation
phase of transcription by Pol II [23]. c-Myc interacts with CycT1,
the regulatory component of P-TEFb, and controls the elongation
phase of transcription of Pol II [25,26,27]. P-TEFb is globally
required for the generation of mRNAs and gene expression
[27,47] and is recruited to genes by a variety of transcription
factors [23,48]. Our results demonstrate that miR-34a suppresses
assembly and function of the c-Myc complex that elongates
transcription. It is known that P-TEFb is involved in aberrant
transcriptional elongation in mixed-lineage leukemia (MLL)
[49,50]. Various tumor cell lines overexpress P-TEFb and CycT1
overexpression promotes transformation and tumor growth [51].
Our study demonstrates here that miR-34a abrogates the c-Myc-
P-TEFb complex by targeting c-Myc. Accumulating evidence has
shown the importance of P-TEFb in malignancy, thus linking
miR-34a to P-TEFb is a significant finding in cancer biology. Our
study partly gives an account of the global and profound effects of
miR-34a on the cellular processes demonstrated here and in
previous reports [4,5,7,8].
As far as we know, the effects of microRNAs on the assembly of
protein complexes have never been reported. Here we report the
effects of miR-34a on the assembly of c-Myc functional complexes,
Figure 5. c-Myc overexpression partially rescues RhoA suppression by miR-34a. (A) PC-3 cells were transiently transfected with pCMV6-
ENTRY only or pCMV6-ENTRY-c-Myc for 8 h followed by transient transfection with pre-miR negative control (NC) or pre–miR-34a for 72 h. Protein
level was analyzed by Western blot. (B) c-Myc expression partially rescues inhibition of invasion induced by miR-34a. PC3 cells were transiently
transfected with pCMV6-ENTRY only (control) or pCMV6-ENTRY-c-Myc for 8 h followed by transfection with pre-miR negative control (NC) or pre–miR-
34a for 48 h. The cells were harvested and subjected to transwell invasion assay. *, P,0.05 compared with control. (C) Representative images of
invaded cells.
doi:10.1371/journal.pone.0029722.g005
miR-34a Targets c-Myc Transcriptional Complexes
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e29722
the c-Myc–Skp2–Miz1 and c-Myc-P-TEFb complexes. c-Myc
activates a variety of genes as part of a protein complex, regulates
transcriptional elongation and mainly functions through different
complexes with other proteins. The effects of miR-34a on these c-
Myc functional complexes provide direct evidence of how miR-
34a functions to suppress c-Myc. The c-Myc complexes which
were induced by miR-34a were heterogeneous since the ratios of
the components were different from those in the control
immunocomplexes (Figs. 4C and 6A). These results indicate that
the complexes were altered by miR-34a, suggesting a new complex
assembly. The alteration of the c-Myc complexes by miR-34a also
suggests that the suppression of the assembly of the c-Myc
complexes may involve unknown mechanisms in addition to the
simple reduction in quantity of c-Myc protein by miR-34a since
miR-34a has dramatic effects on cellular processes.
In conclusion we have shown for the first time that miR-34a
suppresses assembly and function of the c-Myc–Skp2–Miz1 complex
that activates RhoA and the c-Myc-pTEFB complex that elongates
transcription of various genes. Therefore, our study reveals a novel
role of miR-34a in the regulation of transcription by c-Myc.
Materials and Methods
Ethics Statement
Formalin-fixed, paraffin-embedded (FFPE) prostate cancer
samples were obtained from the San Francisco Veterans Affairs
(VA) Medical Center. Written informed consent was obtained from
all patients and the study was approved by the UCSF Committee on
Human Research (Approval number: H9058-35751-01). All animal
care was in accordance with the guidelines of the San Francisco
Veterans Affairs Medical Center and the study was approved by the
San Francisco VA IACUC (Protocol number: 08-003-01).
Cell culture and transfection
Human prostate carcinoma cell lines, PC-3, LNCaP and
DU145 and a non-malignant epithelial prostate cell line,
Figure 6. miR-34a suppresses the c-Myc-P-TEFb complex. (A) miR-34a suppresses the formation of the endogenous c-Myc-P-TEFb complex.
PC-3 cells were transiently transfected with pre-miR negative control (NC) or pre–miR-34a for 72 h and total cell lysates were immunoprecipitated
with c-Myc antibody or IgG (control), followed by Western blot analysis. (B) miR-34a suppresses CAD and NUC mRNA expression and DRB revereses
the suppression. PC-3 cells were treated with 20 mM of DRB for 12 h and were transiently transfected with pre-miR negative control (NC) or pre–miR-
34a for 48 h. CAD and NUC mRNA level was analyzed by real-time PCR.
doi:10.1371/journal.pone.0029722.g006
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RWPE-1, were purchased from The American Type Culture
Collection (Manassas, VA). The prostate cancer cell lines were
cultured in RPMI 1640 medium supplemented with 10% fetal
bovine serum (FBS). RWPE-1 cell line was cultured in keratino-
cyte growth medium supplemented with 5 ng/mL human
recombinant epidermal growth factor and 0.05 mg/mL bovine
pituitary extract (Invitrogen, Carlsbad, CA)
Cells in 6-well plates were transfected with 30 nM pre-miR
negative control (NC) or pre-miR-34a (Applied Biosystems, Foster
City, CA) using Lipofectamine 2000 (Invitrogen), according to the
manufacturer’s instructions.
Tissue samples
Formalin-fixed, paraffin-embedded (FFPE) prostate cancer
samples were obtained from the San Francisco Veterans Affairs
Medical Center. All slides were reviewed by a board certified
pathologist for the identification of prostate cancer foci as well as
adjacent normal glandular epithelium.
Generation of stable miR-34a cell lines
An HIV-based lentiviral packaging system including a plasmid
expressing miR-34a or vector control was purchased from GeneCo-
poeia (Rockville, MD). Lentivirus particles were produced by
transfecting lentiviral expression plasmid into 293T cells. PC-3 cells
were infected with the HIV-based lentivirus expressing miR-34a or
vector control (1.56106 infectious units of virus (IFU) (in 20 ml), and
the infected PC-3 cells were selected with puromycin (0.5 ug/ml).
Soft agar colony formation assay
Soft agar colony formation assay was performed by seeding cells
in a layer of 0.35% agar/RPMI/FBS over a layer of 0.5% agar/
RPMI/FBS. RPMI/FBS was added every 5 days to continuously
supply growth supplements to the cells. Cultures were maintained
in a humidified 37uC incubator. On day 14 after seeding, colony
forming efficiency was quantified by light microscopy.
In vivo tumor growth
Suspensions of the stable miR-34a expressing cells or the control
cells (16107 cells in 100 ml RPMI medium) were subcutaneously
injected into female nude mice (strain BALB/c nu/nu; Charles
River Laboratories, Inc., Wilmington, MA, 4–5 weeks old). Tumor
volume was calculated on the basis of width (x) and length (y): x2y/
2, where x,y.
RNA extraction and quantitative real-time PCR
RNA was isolated using the RNeasy mini kit (Qiagen, Valencia,
CA) according to the manufacturer’s instructions. Reverse
transcription reactions were performed using a Reverse Tran-
Figure 7. c-Met overexpression partially rescues suppression of cell invasion by miR-34a. (A) PC-3 cells were transiently transfected with
pCMV6-ENTRY only or pCMV6-ENTRY-c-Met for 8 h followed by transient transfection with pre-miR negative control (NC) or pre–miR-34a for 72 h. Protein
level was analyzed by Western blot. (B) c-Met expression partially rescues inhibition of invasion induced by miR-34a. PC3 cells were transiently transfected
with pCMV6-ENTRY only (control) or pCMV6-ENTRY-c-Met for 8 h followed by transfection with pre-miR negative control (NC) or pre–miR-34a for 48 h. The
cells were harvested and subjected to transwell invasion assay. *, P,0.05 compared with control. (C) Representative images of invaded cells.
doi:10.1371/journal.pone.0029722.g007
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scription System Kit (Promega, Madison, WI). Quantitative real-
time PCR analysis was performed in triplicate with an Applied
Biosystems Prism7500 Fast Sequence Detection System using
TaqMan universal PCR master mix according to the manufac-
turer’s protocol (Applied Biosystems). Levels of RNA expression
were determined using the 7500 Fast System SDS software version
1.3.1 (Applied Biosystems).
miRNA extraction and quantitative real-time PCR
Total RNA was extracted from laser capture microdissected
(LCM) FFPE tissues and cultured cells using a miRNeasy FFPE kit
(Qiagen, Valencia, CA) and an RNeasy mini kit (Qiagen)
according to the manufacturer’s instructions. Reverse transcription
reactions were performed using a Reverse Transcription System
Kit (Applied Biosystems Inc., Foster City, CA). Quantitative real-
time PCR analysis was performed as described above.
Plasmids
Putative target sites of the 39UTR were cloned into the PmeI-
XbaI site of the dual luciferase pmirGLO vector (Promega,
Madison, WI). For mismatch constructs, 6 mismatches were
introduced in the putative target site.
A human c-Myc expression vector was constructed by
subcloning the full-length cDNA of c-Myc (Invitrogen, Carlsbad,
CA) into the HindIII–XhoI site of the pCMV6-ENTRY vector
(Origene).
c-Met expression vector (human ORF Myc-DDK-tagged ORF
clone of Homo sapiens met proto-oncogene) was purchased from
Origene (Rockville, MD).
Cell viability assay
Cell viability was measured using CellTiter 96 Aqueous One
Solution Cell Proliferation Assay (Promega, Madison, WI), a
colorimetric assay which measures the activity of reductase
enzymes. Cells were seeded at a density of 16103 cells per well
in flat bottomed 96-well plates. At the indicated times, CellTiter 96
Aqueous One reagent was added to each well according to the
manufacturer’s instructions. Cell viability was determined by
measuring the absorbance at 490 nm using a kinetic microplate
reader (Spectra MAX 190; Molecular Devices Co., Sunnyvale,
CA). Data are the mean 6 standard deviation (SD) of 3
independent experiments.
Apoptosis analysis
Apoptosis was measured using flow cytometry (Cell Lab
Quanta SC, Beckman Coulter, Brea, CA) with Annexin-V-
FITC/7-AAD labeling. Measurements were repeated indepen-
dently three times.
Transwell invasion assay
PC-3 cells were grown in DMEM containing 10% FBS. Culture
inserts of 8-mm pore size (Transwell; Costar) were coated with
Matrigel (BD Biosciences, San Jose) (100 mg per well) and placed
into the wells of 24-well culture plates. In the lower chamber,
500 ml of DMEM containing 10% FBS was added and 16105 cells
were seeded to the upper chamber. After 48 hours of incubation at
37uC with 5% CO2, the number of cells that had migrated
through the pores was fixed with 10% formalin and stained with
0.05% Crystal Violet. Crystal Violet was solubilized with methanol
and absorbance (540 nm) of the solution was measured by a
kinetic microplate reader (Spectra MAX 190; Molecular Devices
Co., Sunnyvale, CA). Data are the mean 6 S.D. of 3 independent
experiments.
Western blot
Protein extracts were resolved by SDS-PAGE and transferred to
polyvinylidene fluoride membranes (Hybond-P; GE Healthcare,
Piscataway, NJ), followed by incubation with the indicated
primary and secondary antibodies conjugated to horseradish
peroxidise (GE Healthcare). Signals were detected using the ECL
detection system (Amersham ECL plus Western Blotting detection
system, Fairfield, CT). Antibodies against c-Myc, RhoA, Skp2 and
GAPDH were purchased from Cell Signaling Technology
(Danvers, MA). Antibodies against Miz1, Max, Cdk9, ARHGEF3
and ARHGEF18 were purchased from GeneTex (Irvine, CA). An
antibody against CycT1 was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA).
Luciferase reporter assay
Cells in 24-well plates were transfected with 30 nM pre-miR
negative control (NC) or pre-miR-34a (Applied Biosystems) using
Lipofectamine 2000 (Invitrogen), according to the manufacturer’s
instructions. Transfections of plasmids were perfomed using
FuGENE HD (Roche Diagnosis, Basel, Switzerland) according
to the manufacturer’s instructions. All transfection experiments
were performed in triplicate. Luciferase activity was assayed at
48 h after transfection, using a dual-luciferase reporter assay
system (Promega).
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitations were performed using the
Chromatin Immunoprecipitation Assay Kit (Epigentek, Brooklyn,
NY) according to manufacturer’s instructions. DNA was sheared
by sonication. A 1% portion of the sheared DNA–protein complex
was used for an input DNA sample. Antibodies against c-Myc or
RNA polymerase II (Millipore, Billerica, MA) or normal rabbit
IgG (Millipore) was used for immunoprecipitation. Real-time PCR
quantitation of ChIP was performed in triplicate, normalized by
input, and expressed as a fold increase over the control. Primers
used for real-time PCR were as follows: RhoA E-box5/6, 59 -
CTTCGCGTGCGTGAAGAGTTG-39 and 59-CATCCACTA-
TTGCTCAGGAGC-39; GAPDH promoter, 59-TACTAGCG-
GTTTTACGGGCG-39 and 59-TCGAACAGGAGGAGCAGA-
GAGCGA-39.
Immunoprecipitation (IP)
Cells were lysed in buffer containing 250 mM NaCl, 50 mM
HEPES pH 7.5, 0.1% Nonidet P40, 5 mM EDT and a protease
inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). Protein A/G-
Sepharose beads (Santa Cruz Biotechnology) were added to the
lysate for 60 minutes at 4uC for preclearance. The precleared
lysate was incubated with an anti-c-Myc antibody (Cell Signaling
Technology) or normal rabbit IgG (Millipore) and protein A/G-
Sepharose beads overnight at 4uC. The protein A/G-Sepharose
beads were washed with the lysis buffer. The proteins were
separated by SDS-PAGE and analyzed by Western blot.
Statistical analysis
Data are shown as mean values 6 standard deviation (SD). The
Student’s t-test was used to compare the two different groups. P
values of less than 0.05 were regarded as statistically significant
(n = 3).
Supporting Information
Figure S1 miR-34a expression in PC-3 cells. (A) PC-3 cells
were transfected with 30 nM pre-miR negative control (NC) or
pre-miR-34a. miR-34a expression at 72 h of the transfection was
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analyzed by real-time PCR and was normalized to that of the
control (NC). *, P,0.05 compared with control. (B) PC-3 cells
were infected with the HIV-based lentivirus expressing miR-34a
or vector control, and the infected PC-3 cells were selected with
puromycin. miR-34a expression was analyzed by real-time PCR
and was normalized to that of the control. *, P,0.05 compared
with control.
(TIF)
Figure S2 miR-34a suppresses proliferation of prostate
cancer cells. (A) Prostate cancer cells were seeded at a density of
1.56103 cells per well in 96-well plates. The cells were transiently
transfected with pre-miR negative control (NC) or pre-miR-34a
and cell viability was assayed at the indicated times. *, P,0.05
compared with control. (B) PC-3 cells were transiently transfected
with pre-miR negative control (NC) or pre-miR-34a for 72 h.
miR-34a induces morphological changes in PC-3 cells.
(TIF)
Figure S3 miR-34a induces apoptosis in PC-3 cells. PC-3
cells were transfected with pre-miR negative control (NC) or pre-
miR-34a for 3 days. PC-3 cells were stained with AnnexinV-
FITC/7-AAD and apoptosis was analyzed by flow cytometry.
(TIF)
Figure S4 miR-34a target sequences of c-Met and c-
Myc.
(TIF)
Table S1 Clinical data of laser capture microdissected
(LCM) prostate cancer tissues.
(XLSX)
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